SCHEMBL13640769

SCHEMBL13640769

COCCOC(=O)N1CC2(CCN(C3CCCCC(NC(=O)OC4CCC4)C3)CC2)c2cc(F)ccc21

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SETD2 Q9BYW2 4/20 0.34
NSD2 O96028 1/20 0.34
CYP2C8 P10632 1/20 0.34
DRD2 P14416 1/20 0.34
HTR1B P28222 1/20 0.34
AXL P30530 3/20 0.34
MERTK Q12866 3/20 0.34
CSNK1D P48730 2/20 0.34
CTSS P25774 2/20 0.34
IDO1 P14902 1/20 0.34
FGFR1 P11362 1/20 0.34
KDR P35968 1/20 0.34
CYP2D6 P10635 1/20 0.33
DPP4 P27487 1/20 0.33
DPP8 Q6V1X1 1/20 0.33
DPP9 Q86TI2 1/20 0.33
DPP7 Q9UHL4 1/20 0.33
CCNE1 P24864 1/20 0.33
CDK2 P24941 1/20 0.33
GSK3B P49841 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13640827 0.94 IDO1 (0.35) SETD2NSD2CYP2C8DRD2HTR1B
SCHEMBL13640843 0.94 IDO1 (0.35) SETD2NSD2CYP2C8DRD2HTR1B
SCHEMBL13640736 0.94 CTSS (0.36) SETD2NSD2CYP2C8DRD2HTR1B
SCHEMBL13640942 0.94 CTSS (0.36) SETD2NSD2CYP2C8DRD2HTR1B
SCHEMBL13640819 0.92 MEN1 (0.37) SETD2NSD2CYP2C8DRD2HTR1B
SCHEMBL13641052 0.92 IDO1 (0.34) SETD2NSD2CYP2C8DRD2HTR1B
SCHEMBL13640717 0.91 CTSS (0.35) SETD2NSD2CYP2C8DRD2HTR1B
SCHEMBL13641092 0.90 CTSS (0.37) SETD2DRD2CTSSIDO1DPP4
SCHEMBL13640956 0.88 AXL (0.35) SETD2NSD2CYP2C8DRD2HTR1B
SCHEMBL13640774 0.88 CTSS (0.36) SETD2AXLMERTKCTSSIDO1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8497295-B2 Spiroindoline modulators of muscarinic receptors VERTEX PHARMACEUTICALS INCORPORATED (US) 2013-07-30 US disclosed
US-20120283243-A1 Spiroindoline Modulators of Muscarinic Receptors VERTEX PHARMACEUTICALS INCORPORATED (US) 2012-11-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120283243-A1 Spiroindoline Modulators of Muscarinic Receptors CHRM3, CHRM2, CHRM5 SETD2 3573/4885NSD2 3039/4885CYP2C8 1286/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.